All Pathways
NeurologyManagement

Multiple Sclerosis Acute Relapse Management

Multiple Sclerosis Acute Relapse Management: Suspected MS Relapse → Confirm True Relapse → Pseudorelapse? → Treat Underlying Trigger.

Pathway Overview

15 steps

Algorithm Steps

15 total

  1. 01Start

    Suspected MS Relapse

    New or worsening neurological symptoms in MS patient

  2. 02Action

    Confirm True Relapse

    Rule out pseudorelapse

    • New symptoms lasting >24 hours
    • No fever or infection present
    • At least 30 days since last relapse
    • Exclude UTI, other infections
    • Check for medication changes
  3. 03Decision

    Pseudorelapse?

    Transient worsening due to other factors

    • Infection (UTI most common)
    • Fever, heat exposure
    • Stress, fatigue
    • Uhthoff's phenomenon
  4. Pseudorelapse
  5. 04Action

    Treat Underlying Trigger

    Address pseudorelapse cause

    • Treat infection (antibiotics if UTI)
    • Reduce body temperature
    • Rest, hydration
    • Symptoms resolve when trigger addressed
  6. True relapse
  7. 05Decision

    Assess Relapse Severity

    Mild vs moderate/severe

    • Sensory-only: often mild
    • Motor weakness: moderate/severe
    • Optic neuritis: moderate
    • Brainstem symptoms: can be severe
    • Functional impairment level
  8. Mild
  9. 06Action

    Mild Relapse

    Observation may be reasonable

    • Purely sensory symptoms
    • Minimal functional impact
    • Steroids optional
    • Steroids shorten duration, not final outcome
    • Patient preference matters
  10. If patient wants treatment
  11. 07Action

    High-Dose Corticosteroids

    First-line for moderate/severe relapse

    • IV methylprednisolone 1g daily × 3-5 days
    • OR high-dose oral prednisone 1250 mg daily × 3-5 days
    • No taper typically needed for short course
    • Shortens relapse duration
    • Does NOT affect long-term outcome
  12. 08Warning

    ⚠️ Steroid Precautions

    Monitor for adverse effects

    • Check glucose (especially in diabetics)
    • GI prophylaxis (PPI if needed)
    • Insomnia, mood changes common
    • Avoid in active infection
    • Caution in osteoporosis
  13. 09Decision

    Response to Steroids?

    Evaluate after 5-7 days

    • Most improve within 3-5 days
    • Full recovery may take weeks
    • Incomplete recovery common
  14. Improving
  15. 10Action

    Good Response

    Continue observation

    • Monitor for full recovery
    • May take weeks to months
    • Physical therapy if motor deficit
    • Review DMT efficacy
  16. 11Action

    Review DMT Strategy

    Relapse indicates possible DMT failure

    • First relapse on DMT: may continue same
    • Multiple relapses: consider switching
    • Escalate to higher-efficacy DMT
    • Discuss with MS specialist
  17. 12Outcome

    Follow-up Plan

    Post-relapse care

    • Neurology follow-up in 4-6 weeks
    • Consider repeat MRI in 3 months
    • DMT adherence counseling
    • Patient education on relapse signs
  18. 13Action

    Rehabilitation

    Maximize recovery

    • Physical therapy for motor deficits
    • Occupational therapy for function
    • Vision therapy for optic neuritis
    • Cognitive rehabilitation if needed
  19. Path rejoins step 12Shared downstream outcome
  20. No improvement
  21. 14Action

    Poor or No Response

    Consider escalation

    • Additional steroid course (controversial)
    • Plasma exchange (PLEX)
    • ACTH gel (Acthar) alternative
    • Specialist consultation
  22. 15Action

    Plasma Exchange (PLEX)

    For steroid-refractory severe relapse

    • 5-7 exchanges over 10-14 days
    • Best evidence for severe relapses
    • Optic neuritis, myelitis, brainstem
    • Requires central access
    • ~40-50% response rate if steroids fail
  23. Path rejoins step 11Shared downstream outcome
  24. If resolving
  25. Path rejoins step 12Shared downstream outcome
  26. Moderate/Severe
  27. Path rejoins step 07Shared downstream outcome

Guideline Source

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis - AAN

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Does not address DMT selection in detail
  • PLEX availability varies by center
  • Pseudorelapse must be ruled out
  • Pediatric MS may differ

Applicable Regions

USEUglobal

EU: ECTRIMS recommendations similar

US: AAN guidelines followed

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Multiple Sclerosis Acute Relapse Management?

The Multiple Sclerosis Acute Relapse Management is a management clinical algorithm for Neurology. It provides a structured decision tree to guide clinical decision-making, based on Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis - AAN.

What guideline is the Multiple Sclerosis Acute Relapse Management based on?

This algorithm is based on Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis - AAN (DOI: 10.1212/WNL.0000000000005347).

What are the limitations of the Multiple Sclerosis Acute Relapse Management?

Known limitations include: Does not address DMT selection in detail; PLEX availability varies by center; Pseudorelapse must be ruled out; Pediatric MS may differ. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Multiple Sclerosis Acute Relapse Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free